![](https://webarchive.library.unt.edu/eot2008/20090509154025im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090509154025im_/http://www.cancer.gov/images/spacer.gif)
anakinra A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist with potential antineoplastic activity. Anakinra binds to the IL-1 receptor, thereby blocking the binding of the IL-1 to and activation of its receptor. Blockade of IL-1 activity may inhibit the cascade of downstream pro-angiogenic factors such as vascular endothelial cell growth factor, tumor necrosis factor-alpha, and IL-6, resulting in inhibition of tumor angiogenesis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090509154025im_/http://www.cancer.gov/images/spacer.gif)
Synonyms: | ![](https://webarchive.library.unt.edu/eot2008/20090509154025im_/http://www.cancer.gov/images/spacer.gif) | IL-1ra interleukin-1 receptor antagonist | | ![](https://webarchive.library.unt.edu/eot2008/20090509154025im_/http://www.cancer.gov/images/spacer.gif) | US brand name: | ![](https://webarchive.library.unt.edu/eot2008/20090509154025im_/http://www.cancer.gov/images/spacer.gif) | Kineret | | ![](https://webarchive.library.unt.edu/eot2008/20090509154025im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20090509154025im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509154025im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509154025im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090509154025im_/http://www.cancer.gov/images/spacer.gif) |